Clinical Trials on Fallopian Tube Diseases

Total 377485 results

National Cancer Institute (NCI)

Active, not recruiting

Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 | Stage IIIB Fallopian Tube Cancer... and other conditions

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Withdrawn

ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary... and other conditions

United States
Masonic Cancer Center, University of Minnesota

Completed

IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

FIGO Stage III and IV Ovarian Cancer | FIGO Stage III and IV Fallopian Tube Cancer | FIGO Stage III Primary Peritoneal Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer AJCC v6 and v7 | Stage IV Ovarian Cancer AJCC v6 and v7 | Stage IV Primary Peritoneal Cancer AJCC v7 | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive... and other conditions

United States
Critical Outcome Technologies Inc.
M.D. Anderson Cancer Center; Northwestern Memorial Hospital

Unknown

Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)

Cervical Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Lung Cancer | Endometrial Cancer | Peritoneal Cancer | HNSCC

United States
Amgen

Terminated

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, Belgium, Germany, Italy, United Kingdom, Canada, Denmark, Switzerland, Hong Kong, Austria, Slovakia, Taiwan, Hungary, France, Singapore, Australia, Poland, New Zealand
Boston Scientific Corporation

Completed

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy (nCYT)

Ovarian Diseases | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinoma | Fallopian Tube Adenocarcinoma | High Grade Serous Carcinoma | Ovary Cancer | Adnexal Mass

United States
Yonsei University

Recruiting

Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma

Fallopian Tube Cancer | Primary Peritoneal Cancer | Mucinous Ovarian Cancer

Korea, Republic of
Glycotope GmbH

Completed

PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Ovarian Epithelial Cancer Recurrent

Germany, Hungary, Italy, Poland, Romania, Russian Federation, Spain, United Kingdom
NCIC Clinical Trials Group

Completed

Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada, United Kingdom
Amgen

Completed

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Carcinoma | Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumors | Oncology | Tumors | Metastases | Gynecological Malignancies

Belgium, United States, Australia
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer
Oasmia Pharmaceutical AB

Completed

Study of Paclitaxel in Patients With Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

Ukraine, Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, Hungary, Latvia, Lithuania, Romania, Russian Federation, Serbia, Slovakia, Sweden
Cancer Research UK

Terminated

Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States
Royal Marsden NHS Foundation Trust

Completed

Validation of a Nutrition Screening Tool

Sarcoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United Kingdom
University of Southern Denmark
Ministry of the Interior and Health, Denmark; Danish Clinical Intervention...

Completed

Pharmacogenomics of Paclitaxel in Ovarian Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms

Denmark, Sweden
Grupo Español de Investigación en Cáncer de Ovario

Completed

Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

Spain
Affiliated Cancer Hospital & Institute of Guangzhou...
Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaborators

Recruiting

Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery (EHTASEOCCS)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

China
Shu-Zhong Cui
Xiangya Hospital of Central South University; Wuhan University; Peking University... and other collaborators

Unknown

Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer (EHNPCTASEOC)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

China
Ludwig-Maximilians - University of Munich

Unknown

Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Germany, Netherlands, Hungary
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer
Regeneron Pharmaceuticals

Recruiting

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recurrent Endometrial Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Italy, United Kingdom, Netherlands, Belgium, Australia, France, Israel
University of Colorado, Denver
ImmunoGen, Inc.

Recruiting

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Fallopian Tube Cancer | Peritoneal Cancer | Ovary Cancer

United States
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Suspended

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Peritoneal Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Stage IIIC Fallopian Tube Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IIIC Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Advanced Ovarian Carcinoma

United States
Masonic Cancer Center, University of Minnesota

Completed

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Eli Lilly and Company

Completed

A Study LY2228820 for Recurrent Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Australia, Germany, Belgium
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital

Completed

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Southeastern Gynecologic Oncology
Celgene Corporation

Completed

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Southern Illinois University

Completed

Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
National Cheng-Kung University Hospital

Completed

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer (Trientine)

Fallopian Tube Cancer | Peritoneal Carcinoma | Ovarian Neoplasms Malignant (Excl Germ Cell)
Shanghai Gynecologic Oncology Group
Fudan University; Shanghai Zhongshan Hospital; Shanghai Jiao Tong University...

Completed

First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer (AICE)

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Bulky Stage IIIC and IV Epithelial Ovarian Cancer

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Bayer

Terminated

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
ImmunoGen, Inc.
GOG Foundation

Recruiting

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Korea, Republic of, Spain, Australia, Canada, United Kingdom, Italy, Belgium, Czechia, Philippines, Israel
Sun Yat-sen University

Not yet recruiting

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cancer | High Grade Serous Adenocarcinoma of Ovary | High Grade Endometrioid Ovarian Cancer | Fallopian-tube Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Advanced Pancreatic Adenocarcinoma | Platinum-Resistant... and other conditions

United States
Dana-Farber Cancer Institute
National Institute of Nursing Research (NINR)

Withdrawn

SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care (SIGNAL)

Cervical Cancer | Gynecologic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Uterine Cancer

United States
Morphotek

Completed

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Germany
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
Krankenhaus Barmherzige Schwestern Linz

Withdrawn

HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma (HIPEC)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Austria
Shanghai Gynecologic Oncology Group
Fudan University

Not yet recruiting

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

China
University of Oklahoma

Terminated

Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Uterine Cancer

United States
Onxeo

Completed

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Epithelial Ovarian Cancer

United States, Denmark, United Kingdom
National Cancer Institute (NCI)

Completed

SU5416 and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Peritoneal Neoplasm | Fallopian Tube Neoplasm

United States
John Stoddard Cancer Center at Iowa Methodist Medical...

Unknown

Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
University of Southern Denmark
Ministry of the Interior and Health, Denmark; Danish Clinical Intervention...

Completed

Pharmacogenomics of Paclitaxel in Ovarian Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms

Denmark

Clinical Trials on Fallopian Tube Diseases

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations